CTFA comments
This article was originally published in The Rose Sheet
Executive Summary
FDA's Voluntary Cosmetic Product Reporting Program provides valuable "Use level information...for cosmetic ingredients and formulas" to the Cosmetic Ingredient Review Expert Panel for use in developing ingredient review priorities, Cosmetic, Toiletry and Fragrance Association says in Aug. 12 comments to FDA. Agency announced it was seeking feedback on the program earlier this summer (1"The Rose Sheet" June 13, 2005, In Brief). CTFA adds it will continue to encourage cosmetic companies to file ingredient statements with FDA and work with the agency to make the program "more efficient." Trade group recently urged FDA to strengthen the program in a letter to the Center for Food Safety & Applied Nutrition regarding FY 2006 program priorities (2"The Rose Sheet" July 25, 2005, p. 5)...
You may also be interested in...
CFSAN Reinforcement Of Cosmetic Authority Should Be “A” List In ’06 – CTFA
Clarification of FDA's authority to ensure the safety of cosmetics through its work with the Cosmetic Ingredient Review panel should be the "central focus" of the Center for Food Safety & Applied Nutrition's Office of Cosmetics and Colors in FY 2006, the Cosmetic, Toiletry and Fragrance Association states in July 19 comments to the agency
Cosmetic reporting
FDA is requesting public comments on Cosmetic Product Voluntary Reporting Program, agency announces in June 13 Federal Register 1notice. Information sought by FDA includes feedback on necessity of the program and ways to improve it. Agency notes electronic filing system, expected to reduce burden on manufacturers, likely will be implemented this summer. FDA estimates annual total hour burden at 742 hours, 75% of the burden reported in 2002 due to drop in submissions. "However, the number of respondents doubled, and FDA attributes this to increased interest in the program," agency states, adding it expects an uptick in submissions in the next three years. Comments are due Aug. 12...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.